William Waddill - 09 Jan 2023 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role
Director
Signature
/s/William Waddill
Issuer symbol
ARWR
Transactions as of
09 Jan 2023
Net transactions value
-$96,000
Form type
4
Filing time
11 Jan 2023, 19:23:17 UTC
Previous filing
13 Jun 2022
Next filing
18 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Sale $96,000 -3,200 -10% $30.00 28,950 09 Jan 2023 Direct F1
transaction ARWR Common Stock Award $0 +7,867 +27% $0.000000 36,817 10 Jan 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARWR Common Stock Award $0 +4,593 $0.000000 4,593 10 Jan 2023 Common Stock 4,593 $33.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 Represents shares underlying restricted stock units, which will vest in one installment on the first anniversary of the grant date.
F3 Represents options, which will vest in one installment on the first anniversary of the grant date.